Anti-microbial/Anti-fungal Tests Market

Market Survey on Anti-microbial/Anti-fungal Tests Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment

An In-depth Market Insights of Anti-microbial/Anti-fungal Tests Market including Molecular Based Tests, Phenotypic Resistance Tests, Complex Test Panels, Mass Spectrometry, and Rapid Diagnostic Tests Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others

Request Sample

Anti-microbial/Anti-fungal Tests Market Outlook (2022 to 2032)

[268 Pages Report] The global anti-microbial/anti-fungal tests market is expected to reach US$ 2.5 Billion by the end of 2022. Growth in the market is predicted to expand at a CAGR rate of 5.7% and surpass ~US$ 4.5 Billion by 2032. Based on test type, the molecular-based tests led the market with a share of nearly 53.5% in 2021.

Attributes	Key Insights
Anti-microbial/Anti-fungal Tests Market Value 2021	US$ 2.4 Billion
Estimated Market Size 2022	US$ 2.5 Billion
Projected Market Value 2032	US$ 4.5 Billion
CAGR 2022 to 2032	5.7%
Market Share of Top 5 Countries	55.0%

Microorganism screening to create novel antibiotics has been successfully pursued for numerous years by the researcher. Fungus and bacteria often generate antibiotics. Bacteria are consumed in a variety of fields, including agriculture. In the pharmaceutical and veterinary industries, an antimicrobial is a substance that kills or inhibits bacterial growth.

Antibiotics are employed against antifungals, and bacteria are utilized against fungi in these cases. Antimicrobial chemotherapeutic use antimicrobial drugs to combat infection, and antimicrobial prophylaxis uses antimicrobial medicines to prevent infection. Antimicrobial susceptibility tests can help physicians choose the best medicine and dosage for difficult-to-treat infections.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Anti-microbial/Anti-fungal Tests Market from 2012 to 2021 Vs Demand Outlook for 2022 to 2032

As per Future Market Insights (FMI), the anti-microbial/anti-fungal tests market was approximately 15.4% of the overall ~US$ 15.6 Billion global rapid testing kits market in 2021. Overall sales in the anti-microbial/anti-fungal tests market surged at a CAGR of 5.6% from 2012 to 2021.

Growth in the market is primarily attributed to the increased prevalence of infectious diseases across the globe. Furthermore, rising rates of surgical site infections and other related issues are propelling sales in the antimicrobial antifungal test market. Further, advancements in biotechnology and in diagnostic procedures are facilitating growth in the market.

As a number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, healthcare professionals are focusing on antimicrobial susceptibility testing (AST). Minimum inhibitory concentrations (MICs) are provided by a rapid multiplexed AST platform at a reasonable cost, allowing for the rapid determination of effective targeted therapy. This is resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.

The market witnessed prolific growth as the use of antibiotics and antifungal skyrocketed. Further, nosocomial bacterial superinfections are more common than community-acquired coinfections. This is particularly among ICU patients and those taking immunosuppressive therapy. On the back of these factors, the global anti-microbial/anti-fungal tests market is expected to grow at a CAGR of 5.7% during the forecast period.

Anti-microbial/Anti-fungal Tests Market

What are the Key Opportunities in the Anti-microbial/Anti-fungal Tests Kit Market?

Favorable Government Initiatives and Awareness Programs to Fuel the Growth

Favorable government initiatives and the development of healthcare infrastructure across the globe is the key factor propelling sales in the global anti-microbial/anti-fungal tests kit market. Advancements in point-of-care (POC) detection methods that enable decentralised, quick, sensitive, low-cost COVID-19 infection diagnostics are spuuring the growth in the market.

Rising awareness by government bodies has positively impacted manufacturers and healthcare service providers. For instance, WAAW was formerly known as World Antibiotic Awareness Week, which is now changed to World Antimicrobial Awareness Week in 2020. This reflects WAAW's expanded scope, which now includes all antimicrobials such as antifungals, antibiotics, antiparasitics, and antivirals.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining Demand for Anti-microbial/Anti-fungal Tests?

The lack of an innovation culture and stringent regulatory approvals might hamper the demand in the market. In general, healthcare providers and medical workers are risk-averse and resistant to policy reforms. In the realm of in-vitro diagnostics, there have been numerous instances where physicians have been highly reluctant to advance. Furthermore, the administration and organization of diagnostic services may further restrict the market in the forecast period's coming years.

Further, the complexity in interpreting the paradoxical growth phenomenon seen with echinocandins and yeasts (which differs from the trailing effect) and uncertainty for caspofungin testing is due to the molecule's lack of stability in culture media. These factors cumulatively might negatively affect the growth in the anti-microbial/anti-fungal tests market.

Country-wise Insights

How will the Sales in the USA Anti-microbial/Anti-fungal Tests Market Increase?

Growing Preference for Diagnostic Tests to Boost the Sales

The USA dominated the North American anti-microbial/anti-fungal tests market with a total share of about 89.4% in 2021. Growth in the market is primarily underpinned by the growing preference for diagnostic tests recommended by physicians before any type of treatment. Furthermore, widespread awareness of the adverse effects of particular medications, and patients frequently prefer to be fully diagnosed before seeking treatment.

Will China Retain its Dominance in Anti-microbial/Anti-fungal Tests Market?

Rising Prevalence of NIC and Diabetes Mellitus to Facilitate the Growth in China

China held approximately 7.5% share in the global anti-microbial/anti-fungal tests market in 2021, as per FMI. Sales in the market are projected to display growth at a CAGR of 7.1% during the forecast period.

Due to the increased number of immunocompromised individuals, invasive fungal infections (IFIs), especially those caused by uncommon yeasts, are becoming more common. Invasive candidiasis is the key concern with significant morbidity and mortality.

It affects patients of all ages, including those with malignancies, non-immunocompromised (NIC) and HIV-negative immunocompromised (IC) patients, individuals among the severely ill, typically hospitalised to an intensive care unit (ICU), or diagnosed with diabetes mellitus or uncontrolled hyperglycaemia needing invasive mechanical ventilation.

How Big is the Opportunity in Germany's Anti-microbial/Anti-fungal Tests Market?

Germany Anti-microbial/Anti-fungal Tests Market to Gain from Rising Incidence of Fungal Infection

Germany is set to exhibit a CAGR growth of nearly 7.1% in the Europe anti-microbial/anti-fungal tests market during the forecast period. Candida glabrata is the second most common fungal infection in Germany, causing candidaemia and invasive candidiasis.

This yeast is known for its quick acquisition of antifungal medication resistance. Furthermore, with the increasing prevalence of chronic and infectious diseases, the ageing population will demand the anti-microbial/anti-fungal tests market.

Category-wise Insights

Which Anti-microbial/Anti-fungal Tests Type is Driving the Growth?

Molecular-Based Tests to Gain Immense Traction through 2022 & Beyond

Molecular-based tests are expected to lead the market, registering growth at a CAGR of 5.3% during the forecast period. The segment is expected to account for a share of more than 50.0% in the global anti-microbial/anti-fungal tests market. Owing to their factors of increasing susceptibility, minimization of false positive results, better turnaround time, and possesses wide applications.

Based on infection, antimicrobial resistance held a revenue share of 48% in 2021 and is expected to display gradual growth over the forecast period. Antimicrobial resistance (AMR) emerges when fungi, viruses, bacteria, and parasites evolve over a period. Therefore it shows no longer responds to antibiotics treatment, making infections more challenging to treat and increasing the risk of disease spread, major illness, and death. This is expected to fuel revenue growth over the forecast period.

Which is the Leading End User in Anti-microbial/Anti-fungal Tests Market?

Nearly 2 out of 5 Sales are Contributed by Hospitals

As per FMI, hospitals held the market with the highest share value of 36.9% and are expected to maintain the lead over the upcoming decade. Increasing hospital-acquired infections and increasing inpatient admissions are propelling sales of the overall anti-microbial/anti-fungal tests market.

Competitive Landscape

With several competitors in the anti-microbial/anti-fungal tests market, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.

In July 2022, Roche announced that Elecsys HCV Duo immunoassay is now available in countries that accept the CE Mark. Elecsys HCV Duo is the only immunoassay on the market that can determine hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
In June 2022, Meridian Bioscience, Inc., a global leader in diagnostic testing solutions and life science raw materials, introduced two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix and Lyo-Ready Direct RNA/DNA qPCR Stool Mix. These novel master mixes increase the molecular detection of DNA and RNA from crude faecal materials while allowing diagnostic procedures to be room temperature stabilised.

Report Scope as per Anti-microbial/Anti-fungal Tests Industry Analysis

Attribute	Details
Estimated Market Size 2022	US$ 2.5 Billion
Projected Market Value 2032	US$ 4.5 Billion
CAGR 2022 to 2032	5.7%
Forecast Period	2012 to 2021
Historical Data Available for	2022 to 2032
Market Analysis	US$ Million for Value
Key Regions Covered	North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa
Key Market Segments Covered	Tests, Infection, End User, and Region
Key Companies Profiled	Abbott Laboratories bioMérieux SA Bio-Rad Laboratories Inc Bruker Corporation Danaher Corporation Erba Mannheim F. Hoffmann-La Roche AG Luminex Corporation Meridian Bioscience Inc Norgen Biotek Corp Omega Diagnostics Group Plc Qiagen N.V Quidel Corporation Thermo Fisher Scientific Inc

Key Market Segments Covered in Anti-microbial/Anti-fungal Tests Industry Research

By Tests Type:

Molecular Based Tests
- PCR Test
- DNA Microarray
Phenotypic Resistance Tests
Complex Test Panels
Mass Spectrometry
Rapid Diagnostic Tests
- E-Test Antibiotic/Antifungal Strips
- Biosensor Platforms

By Infection Type:

Antimicrobial Resistance
- Methicillin-Resistant Staphylococcus Aureus
- Vancomycin-Resistant Enterococcus
- Multi-Drug-Resistant Mycobacterium tuberculosis
- Carbapenem-Resistant Enterobacteriaceae gut bacteria
Microbial Infection
Antifungal Resistance
- Candida infections
- Aspergillus infection
- Fusariosis
- Others
Fungal Infection

By End User:

Hospitals
Ambulatory Surgical Centers
Clinics
Community Health Centers
Reference Laboratories

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)

Frequently Asked Questions

How much was the anti-microbial/anti-fungal tests market worth in 2021?

The global anti-microbial/anti-fungal tests market is worth US$ 2.4 Billion in 2021 and is set to expand 1.7X over the next ten years.

What is the sales forecast for the anti-microbial/anti-fungal tests market through 2032?

The anti-microbial/anti-fungal tests market is expected to reach US$ 4.5 Billion by the end of 2032, with sales revenue expected to register a 5.7% CAGR.

What are the key trends shaping the anti-microbial/anti-fungal tests market?

The growing geriatric population and innovative product development, increasing prevalence of antimicrobial resistance cases are some of the key trends in this market.

Which are the top five countries driving demand for anti-microbial/anti-fungal tests?

USA, India, China, Germany, and Japan are expected to drive demand for the anti-microbial/anti-fungal tests industry.

What is the North American market outlook for anti-microbial/anti-fungal tests?

North America is one of the key markets for anti-microbial/anti-fungal tests, with the USA accounting for about 89.4% of the North American anti-microbial/anti-fungal tests market in the year 2021.

At what percentage is the demand for anti-microbial/anti-fungal tests expected to register growth in Europe?

Demand for anti-microbial/anti-fungal tests in Europe is expected to register a growth of 5.0% CAGR over the next ten years.

At what percentage is the demand for anti-microbial/anti-fungal tests expected to register growth in MEA?

Demand for anti-microbial/anti-fungal tests in MEA is expected to register a growth of 4.5% over the next ten years.

Which countries are the key producers of anti-microbial/anti-fungal tests?

China and the USA, Germany are the key producers of anti-microbial/anti-fungal tests.

Who are the key players in the anti-microbial/anti-fungal tests market sphere?

Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc., are some of the key players in the anti-microbial/anti-fungal tests industry.

Table of Content

1. Executive Summary | Anti-microbial/Anti-fungal Tests Market

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Epidemiology of Key Indication, By Region

4.2. Key Promotional Strategies

4.3. Patient Journey

4.4. Regulatory Scenario

4.5. Reimbursement Landscape

4.6. PESTEL analysis

4.7. Porter’s analysis

4.8. Value Chain

5. Market Background

5.1. Macro-Economic Factors

5.1.1. Global GDP Growth Outlook

5.1.2. Global Healthcare GDP Growth Overview

5.2. Forecast Factors - Relevance & Impact

5.2.1. Rising Prevalence of infectious diseases.

5.2.2. Increasing Awareness and Adoption.

5.2.3. Increase in rapid diagnostics tests.

5.2.4. Increasing prevalence of antimicrobial resistance patients.

5.3. Market Dynamics

5.3.1. Drivers

5.3.2. Restraints

5.3.3. Opportunity Analysis

5.4. Global Supply Demand Analysis

6. COVID-19 Crisis - Crisis Analysis

6.1. COVID-19 and Impact Analysis

6.2. 2021 Market Scenario

6.2.1. By Tests Type

6.2.2. By Infection Type

6.2.3. By End User

6.2.4. By Region

7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032

7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021

7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Tests Type

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Million) Analysis By Tests Type, 2012 to 2021

8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Tests Type, 2022 to 2032

8.3.1. Molecular-Based Tests

8.3.1.1. PCR Test

8.3.1.2. DNA Microarray

8.3.2. Phenotypic Resistance Tests

8.3.3. Complex Test Panels

8.3.4. Mass Spectrometry

8.3.5. Rapid Diagnostic Tests

8.3.5.1. E-Test Antibiotic/Antifungal Strips

8.3.5.2. Biosensor Platforms

8.4. Market Attractiveness Analysis By Tests Type

9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Infection Type

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Million) Analysis, By Infection Type, 2012 to 2021

9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Infection Type, 2022 to 2032

9.3.1. Antimicrobial Resistance

9.3.1.1. Methicillin-Resistant Staphylococcus Aureus

9.3.1.2. Vancomycin-Resistant Enterococcus

9.3.1.3. Multi-Drug-Resistant Mycobacterium tuberculosis

9.3.1.4. Carbapenem-Resistant Enterobacteriaceae gut bacteria

9.3.2. Microbial Infection

9.3.3. Antifungal Resistance

9.3.3.1. Candida infections

9.3.3.2. Aspergillus infection

9.3.3.3. Fusariosis

9.3.3.4. Others

9.3.4. Fungal Infection

9.4. Market Attractiveness Analysis By Infection Type

10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Million) Analysis, By End User, 2012 to 2021

10.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2022 to 2032

10.3.1. Hospitals

10.3.2. Ambulatory Surgical Centers

10.3.3. Clinics

10.3.4. Community Health Centers

10.3.5. Reference Laboratories

10.4. Market Attractiveness Analysis By End User

11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region

11.1. Introduction

11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021

11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032

11.3.1. North America

11.3.2. Latin America

11.3.3. Europe

11.3.4. East Asia

11.3.5. South Asia

11.3.6. Oceania

11.3.7. Middle East and Africa (MEA)

11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032

12.1. Introduction

12.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

12.3.1. By Country

12.3.1.1. United States of America

12.3.1.2. Canada

12.3.2. By Tests Type

12.3.3. By Infection Type

12.3.4. By End User

12.4. Market Attractiveness Analysis

12.4.1. By Country

12.4.2. By Tests Type

12.4.3. By Infection Type

12.4.4. By End User

12.5. Market Trends

12.6. Key Market Participants - Intensity Mapping

12.7. Drivers and Restraints - Impact Analysis

12.8. Country-Level Analysis & Forecast

12.8.1. USA Market Analysis

12.8.1.1. Introduction

12.8.1.2. Market Analysis and Forecast by Market Taxonomy

12.8.1.2.1. By Tests Type

12.8.1.2.2. By Infection Type

12.8.1.2.3. By End User

12.8.2. Canada Market Analysis

12.8.2.1. Introduction

12.8.2.2. Market Analysis and Forecast by Market Taxonomy

12.8.2.2.1. By Tests Type

12.8.2.2.2. By Infection Type

12.8.2.2.3. By End User

13. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032

13.1. Introduction

13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

13.3.1. By Country

13.3.1.1. Mexico

13.3.1.2. Brazil

13.3.1.3. Argentina

13.3.1.4. Rest of Latin America

13.3.2. By Tests Type

13.3.3. By Infection Type

13.3.4. By End User

13.4. Market Attractiveness Analysis

13.4.1. By Country

13.4.2. By Tests Type

13.4.3. By Infection Type

13.4.4. By End User

13.5. Market Trends

13.6. Key Market Participants - Intensity Mapping

13.7. Drivers and Restraints - Impact Analysis

13.8. Country-Level Analysis & Forecast

13.8.1. Mexico Market Analysis

13.8.1.1. Introduction

13.8.1.2. Market Analysis and Forecast by Market Taxonomy

13.8.1.2.1. By Tests Type

13.8.1.2.2. By Infection Type

13.8.1.2.3. By End User

13.8.2. Brazil Market Analysis

13.8.2.1. Introduction

13.8.2.2. Market Analysis and Forecast by Market Taxonomy

13.8.2.2.1. By Tests Type

13.8.2.2.2. By Infection Type

13.8.2.2.3. By End User

13.8.3. Argentina Market Analysis

13.8.3.1. Introduction

13.8.3.2. Market Analysis and Forecast by Market Taxonomy

13.8.3.2.1. By Tests Type

13.8.3.2.2. By Infection Type

13.8.3.2.3. By End User

14. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032

14.1. Introduction

14.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

14.3.1. By Country

14.3.1.1. Germany

14.3.1.2. Italy

14.3.1.3. France

14.3.1.4. United Kingdom

14.3.1.5. Spain

14.3.1.6. BENELUX

14.3.1.7. Russia

14.3.1.8. Rest of Europe

14.3.2. By Tests Type

14.3.3. By Infection Type

14.3.4. By End User

14.4. Market Attractiveness Analysis

14.4.1. By Country

14.4.2. By Tests Type

14.4.3. By Infection Type

14.4.4. By End User

14.5. Market Trends

14.6. Key Market Participants - Intensity Mapping

14.7. Drivers and Restraints - Impact Analysis

14.8. Country-Level Analysis & Forecast

14.8.1. Germany Market Analysis

14.8.1.1. Introduction

14.8.1.2. Market Analysis and Forecast by Market Taxonomy

14.8.1.2.1. By Tests Type

14.8.1.2.2. By Infection Type

14.8.1.2.3. By End User

14.8.2. Italy Market Analysis

14.8.2.1. Introduction

14.8.2.2. Market Analysis and Forecast by Market Taxonomy

14.8.2.2.1. By Tests Type

14.8.2.2.2. By Infection Type

14.8.2.2.3. By End User

14.8.3. France Market Analysis

14.8.3.1. Introduction

14.8.3.2. Market Analysis and Forecast by Market Taxonomy

14.8.3.2.1. By Tests Type

14.8.3.2.2. By Infection Type

14.8.3.2.3. By End User

14.8.4. UK Market Analysis

14.8.4.1. Introduction

14.8.4.2. Market Analysis and Forecast by Market Taxonomy

14.8.4.2.1. By Tests Type

14.8.4.2.2. By Infection Type

14.8.4.2.3. By End User

14.8.5. Spain Market Analysis

14.8.5.1. Introduction

14.8.5.2. Market Analysis and Forecast by Market Taxonomy

14.8.5.2.1. By Tests Type

14.8.5.2.2. By Infection Type

14.8.5.2.3. By End User

14.8.6. BENELUX Market Analysis

14.8.6.1. Introduction

14.8.6.2. Market Analysis and Forecast by Market Taxonomy

14.8.6.2.1. By Tests Type

14.8.6.2.2. By Infection Type

14.8.6.2.3. By End User

14.8.7. Russia Market Analysis

14.8.7.1. Introduction

14.8.7.2. Market Analysis and Forecast by Market Taxonomy

14.8.7.2.1. By Tests Type

14.8.7.2.2. By Infection Type

14.8.7.2.3. By End User

15. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032

15.1. Introduction

15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

15.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032

15.3.1. By Country

15.3.1.1. India

15.3.1.2. Indonesia

15.3.1.3. Malaysia

15.3.1.4. Thailand

15.3.1.5. Rest of South Asia

15.3.2. By Tests Type

15.3.3. By Infection Type

15.3.4. By End User

15.4. Market Attractiveness Analysis

15.4.1. By Country

15.4.2. By Tests Type

15.4.3. By Infection Type

15.4.4. By End User

15.5. Market Trends

15.6. Key Market Participants - Intensity Mapping

15.7. Drivers and Restraints - Impact Analysis

15.8. Country-Level Analysis & Forecast

15.8.1. India Market Analysis

15.8.1.1. Introduction

15.8.1.2. Market Analysis and Forecast by Market Taxonomy

15.8.1.2.1. By Tests Type

15.8.1.2.2. By Infection Type

15.8.1.2.3. By End User

15.8.2. Indonesia Market Analysis

15.8.2.1. Introduction

15.8.2.2. Market Analysis and Forecast by Market Taxonomy

15.8.2.2.1. By Tests Type

15.8.2.2.2. By Infection Type

15.8.2.2.3. By End User

15.8.3. Malaysia Market Analysis

15.8.3.1. Introduction

15.8.3.2. Market Analysis and Forecast by Market Taxonomy

15.8.3.2.1. By Tests Type

15.8.3.2.2. By Infection Type

15.8.3.2.3. By End User

15.8.4. Thailand Market Analysis

15.8.4.1. Introduction

15.8.4.2. Market Analysis and Forecast by Market Taxonomy

15.8.4.2.1. By Tests Type

15.8.4.2.2. By Infection Type

15.8.4.2.3. By End User

16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032

16.1. Introduction

16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

16.3.1. By Country

16.3.1.1. China

16.3.1.2. Japan

16.3.1.3. South Korea

16.3.2. By Tests Type

16.3.3. By Infection Type

16.3.4. By End User

16.4. Market Attractiveness Analysis

16.4.1. By Country

16.4.2. By Tests Type

16.4.3. By Infection Type

16.4.4. By End User

16.5. Market Trends

16.6. Key Market Participants - Intensity Mapping

16.7. Drivers and Restraints - Impact Analysis

16.8. Country-Level Analysis & Forecast

16.8.1. China Market Analysis

16.8.1.1. Introduction

16.8.1.2. Market Analysis and Forecast by Market Taxonomy

16.8.1.2.1. By Tests Type

16.8.1.2.2. By Infection Type

16.8.1.2.3. By End User

16.8.2. Japan Market Analysis

16.8.2.1. Introduction

16.8.2.2. Market Analysis and Forecast by Market Taxonomy

16.8.2.2.1. By Tests Type

16.8.2.2.2. By Infection Type

16.8.2.2.3. By End User

16.8.3. South Korea Market Analysis

16.8.3.1. Introduction

16.8.3.2. Market Analysis and Forecast by Market Taxonomy

16.8.3.2.1. By Tests Type

16.8.3.2.2. By Infection Type

16.8.3.3. By End User

17. Oceania Market 2017 to 2021 and Forecast 2022 to 2032

17.1. Introduction

17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

17.3.1. By Country

17.3.1.1. Australia

17.3.1.2. New Zealand

17.3.2. By Tests Type

17.3.3. By Infection Type

17.3.4. By End User

17.4. Market Attractiveness Analysis

17.4.1. By Country

17.4.2. By Tests Type

17.4.3. By Infection Type

17.4.4. By End User

17.5. Market Trends

17.6. Key Market Participants - Intensity Mapping

17.7. Drivers and Restraints - Impact Analysis

17.8. Country-Level Analysis & Forecast

17.8.1. Australia Market Analysis

17.8.1.1. Introduction

17.8.1.2. Market Analysis and Forecast by Market Taxonomy

17.8.1.2.1. By Tests Type

17.8.1.2.2. By Infection Type

17.8.1.2.3. By End User

17.8.2. New Zealand Market Analysis

17.8.2.1. Introduction

17.8.2.2. Market Analysis and Forecast by Market Taxonomy

17.8.2.2.1. By Tests Type

17.8.2.2.2. By Infection Type

17.8.2.2.3. By End User

18. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032

18.1. Introduction

18.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

18.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032

18.3.1. By Country

18.3.1.1. GCC Countries

18.3.1.2. Turkey

18.3.1.3. South Africa

18.3.1.4. North Africa

18.3.2. By Tests Type

18.3.3. By Infection Type

18.3.4. By End User

18.4. Market Attractiveness Analysis

18.4.1. By Country

18.4.2. By Tests Type

18.4.3. By Infection Type

18.4.4. By End User

18.5. Market Trends

18.6. Key Market Participants - Intensity Mapping

18.7. Drivers and Restraints - Impact Analysis

18.8. Country-Level Analysis & Forecast

18.8.1. GCC Countries Market Analysis

18.8.1.1. Introduction

18.8.1.2. Market Analysis and Forecast by Market Taxonomy

18.8.1.2.1. By Tests Type

18.8.1.2.2. By Infection Type

18.8.1.2.3. By End User

18.8.2. Turkey Market Analysis

18.8.2.1. Introduction

18.8.2.2. Market Analysis and Forecast by Market Taxonomy

18.8.2.2.1. By Tests Type

18.8.2.2.2. By Infection Type

18.8.2.2.3. By End User

18.8.3. South Africa Market Analysis

18.8.3.1. Introduction

18.8.3.2. Market Analysis and Forecast by Market Taxonomy

18.8.3.2.1. By Tests Type

18.8.3.2.2. By Infection Type

18.8.3.2.3. By End User

18.8.4. North Africa Market Analysis

18.8.4.1. Introduction

18.8.4.2. Market Analysis and Forecast by Market Taxonomy

18.8.4.2.1. By Tests Type

18.8.4.2.2. By Infection Type

18.8.4.2.3. By End User

19. Market Structure Analysis

19.1. Market Analysis by Tier of Companies

19.2. Market Share Analysis of Top Players

19.3. Market Presence Analysis

20. Competition Analysis

20.1. Competition Dashboard

20.2. Competition Benchmarking

20.3. Competition Deep Dive

20.3.1. Abbott Laboratories

20.3.1.1. Overview

20.3.1.2. Product Portfolio

20.3.1.3. Fey Financials

20.3.1.4. Sales Footprint

20.3.1.5. Strategy Overview

20.3.2. bioMérieux SA,

20.3.2.1. Overview

20.3.2.2. Product Portfolio

20.3.2.3. Fey Financials

20.3.2.4. Sales Footprint

20.3.2.5. Strategy Overview

20.3.3. Bio-Rad Laboratories Inc.,

20.3.3.1. Overview

20.3.3.2. Product Portfolio

20.3.3.3. Fey Financials

20.3.3.4. Sales Footprint

20.3.3.5. Strategy Overview

20.3.4. Bruker Corporation,

20.3.4.1. Overview

20.3.4.2. Product Portfolio

20.3.4.3. Fey Financials

20.3.4.4. Sales Footprint

20.3.4.5. Strategy Overview

20.3.5. Danaher Corporation,

20.3.5.1. Overview

20.3.5.2. Product Portfolio

20.3.5.3. Fey Financials

20.3.5.4. Sales Footprint

20.3.5.5. Strategy Overview

20.3.6. Erba Mannheim,

20.3.6.1. Overview

20.3.6.2. Product Portfolio

20.3.6.3. Fey Financials

20.3.6.4. Sales Footprint

20.3.6.5. Strategy Overview

20.3.7. F. Hoffmann-La Roche AG,

20.3.7.1. Overview

20.3.7.2. Product Portfolio

20.3.7.3. Fey Financials

20.3.7.4. Sales Footprint

20.3.7.5. Strategy Overview

20.3.8. Luminex Corporation,

20.3.8.1. Overview

20.3.8.2. Product Portfolio

20.3.8.3. Fey Financials

20.3.8.4. Sales Footprint

20.3.8.5. Strategy Overview

20.3.9. Meridian Bioscience Inc.,

20.3.9.1. Overview

20.3.9.2. Product Portfolio

20.3.9.3. Fey Financials

20.3.9.4. Sales Footprint

20.3.9.5. Strategy Overview

20.3.10. Norgen Biotek Corp.,

20.3.10.1. Overview

20.3.10.2. Product Portfolio

20.3.10.3. Fey Financials

20.3.10.4. Sales Footprint

20.3.10.5. Strategy Overview

20.3.11. Omega Diagnostics Group Plc.,

20.3.11.1. Overview

20.3.11.2. Product Portfolio

20.3.11.3. Fey Financials

20.3.11.4. Sales Footprint

20.3.11.5. Strategy Overview

20.3.12. Qiagen N.V.,

20.3.12.1. Overview

20.3.12.2. Product Portfolio

20.3.12.3. Fey Financials

20.3.12.4. Sales Footprint

20.3.12.5. Strategy Overview

20.3.13. Quidel Corporation,

20.3.13.1. Overview

20.3.13.2. Product Portfolio

20.3.13.3. Fey Financials

20.3.13.4. Sales Footprint

20.3.13.5. Strategy Overview

20.3.14. Thermo Fisher Scientific Inc.

20.3.14.1. Overview

20.3.14.2. Product Portfolio

20.3.14.3. Fey Financials

20.3.14.4. Sales Footprint

20.3.14.5. Strategy Overview

21. Assumptions and Acronyms Used

22. Research Methodology

List of Tables

Table 01: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test

Table 02: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Infection

Table 03: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User

Table 04: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region

Table 05: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country

Table 06: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test

Table 07: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection

Table 08: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User

Table 09: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country

Table 10: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test

Table 11: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection

Table 12: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User

Table 13: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country

Table 14: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test

Table 15: Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Infection

Table 16: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User

Table 17: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country

Table 18: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test

Table 19: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection

Table 20: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User

Table 21: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country

Table 22: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test

Table 23: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection

Table 24: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User

Table 25: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country

Table 26: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test

Table 27: Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Infection

Table 28: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User

Table 29: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country

Table 30: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test

Table 31: Middle East & Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Infection

Table 32: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 01: Global Market Value (US$ Million) Analysis, 2012 to 2021

Figure 02: Global Market Forecast & Y-o-Y Growth, 2022 to 2032

Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2021 to 2032

Figure 04: Global Market Value Share (%) Analysis 2022 and 2032, by Test

Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Test

Figure 06: Global Market Attractiveness Analysis 2022 to 2032, by Test

Figure 07: Global Market Value Share (%) Analysis 2022 and 2032, by Infection

Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Infection

Figure 09: Global Market Attractiveness Analysis 2022 to 2032, by Infection

Figure 10: Global Market Value Share (%) Analysis 2022 and 2032, by End User

Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by End User

Figure 12: Global Market Attractiveness Analysis 2022 to 2032, by End User

Figure 13: Global Market Value Share (%) Analysis 2022 and 2032, by Region

Figure 14: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Region

Figure 15: Global Market Attractiveness Analysis 2022 to 2032, by Region

Figure 16: North America Market Value (US$ Million) Analysis, 2012 to 2021

Figure 17: North America Market Value (US$ Million) Forecast, 2022 to 2032

Figure 18: North America Market Value Share, by Test (2022 E)

Figure 19: North America Market Value Share, by Infection (2022 E)

Figure 20: North America Market Value Share, by End User (2022 E)

Figure 21: North America Market Value Share, by Country (2022 E)

Figure 22: North America Market Attractiveness Analysis by Test, 2022 to 2032

Figure 23: North America Market Attractiveness Analysis by Infection, 2022 to 2032

Figure 24: North America Market Attractiveness Analysis by End User, 2022 to 2032

Figure 25: North America Market Attractiveness Analysis by Country, 2022 to 2032

Figure 26: USA Market Value Proportion Analysis, 2021

Figure 27: Global Vs. USA Growth Comparison, 2021 to 2032

Figure 28: USA Market Share Analysis (%) by Test, 2021 to 2032

Figure 29: USA Market Share Analysis (%) by Infection, 2021 to 2032

Figure 30: USA Market Share Analysis (%) by End User, 2021 to 2032

Figure 31: Canada Market Value Proportion Analysis, 2021

Figure 32: Global Vs. Canada. Growth Comparison, 2021 to 2032

Figure 33: Canada Market Share Analysis (%) by Test, 2021 to 2032

Figure 34: Canada Market Share Analysis (%) by Infection, 2021 to 2032

Figure 35: Canada Market Share Analysis (%) by End User, 2021 to 2032

Figure 36: Latin America Market Value (US$ Million) Analysis, 2012 to 2021

Figure 37: Latin America Market Value (US$ Million) Forecast, 2022 to 2032

Figure 38: Latin America Market Value Share, by Test (2022 E)

Figure 39: Latin America Market Value Share, by Infection (2022 E)

Figure 40: Latin America Market Value Share, by End User (2022 E)

Figure 41: Latin America Market Value Share, by Country (2022 E)

Figure 42: Latin America Market Attractiveness Analysis by Test, 2022 to 2032

Figure 43: Latin America Market Attractiveness Analysis by Infection, 2022 to 2032

Figure 44: Latin America Market Attractiveness Analysis by End User, 2022 to 2032

Figure 45: Latin America Market Attractiveness Analysis by Country, 2022 to 2032

Figure 46: Mexico Market Value Proportion Analysis, 2021

Figure 47: Global Vs Mexico Growth Comparison, 2021 to 2032

Figure 48: Mexico Market Share Analysis (%) by Test, 2021 to 2032

Figure 49: Mexico Market Share Analysis (%) by Infection, 2021 to 2032

Figure 50: Mexico Market Share Analysis (%) by End User, 2021 to 2032

Figure 51: Brazil Market Value Proportion Analysis, 2021

Figure 52: Global Vs. Brazil. Growth Comparison, 2021 to 2032

Figure 53: Brazil Market Share Analysis (%) by Test, 2021 to 2032

Figure 54: Brazil Market Share Analysis (%) by Infection, 2021 to 2032

Figure 55: Brazil Market Share Analysis (%) by End User, 2021 to 2032

Figure 56: Argentina Market Value Proportion Analysis, 2021

Figure 57: Global Vs Argentina Growth Comparison, 2021 to 2032

Figure 58: Argentina Market Share Analysis (%) by Test, 2021 to 2032

Figure 59: Argentina Market Share Analysis (%) by Infection, 2021 to 2032

Figure 60: Argentina Market Share Analysis (%) by End User, 2021 to 2032

Figure 61: Europe Market Value (US$ Million) Analysis, 2012 to 2021

Figure 62: Europe Market Value (US$ Million) Forecast, 2022 to 2032

Figure 63: Europe Market Value Share, by Test (2022 E)

Figure 64: Europe Market Value Share, by Infection (2022 E)

Figure 65: Europe Market Value Share, by End User (2022 E)

Figure 66: Europe Market Value Share, by Country (2022 E)

Figure 67: Europe Market Attractiveness Analysis by Test, 2022 to 2032

Figure 68: Europe Market Attractiveness Analysis by Infection, 2022 to 2032

Figure 69: Europe Market Attractiveness Analysis by End User, 2022 to 2032

Figure 70: Europe Market Attractiveness Analysis by Country, 2022 to 2032

Figure 71: UK Market Value Proportion Analysis, 2021

Figure 72: Global Vs. UK Growth Comparison, 2021 to 2032

Figure 73: UK Market Share Analysis (%) by Test, 2021 to 2032

Figure 74: UK Market Share Analysis (%) by Infection, 2021 to 2032

Figure 75: UK Market Share Analysis (%) by End User, 2021 to 2032

Figure 76: Germany Market Value Proportion Analysis, 2021

Figure 77: Global Vs. Germany Growth Comparison, 2021 to 2032

Figure 78: Germany Market Share Analysis (%) by Test, 2021 to 2032

Figure 79: Germany Market Share Analysis (%) by Infection, 2021 to 2032

Figure 80: Germany Market Share Analysis (%) by End User, 2021 to 2032

Figure 81: Italy Market Value Proportion Analysis, 2021

Figure 82: Global Vs. Italy Growth Comparison, 2021 to 2032

Figure 83: Italy Market Share Analysis (%) by Test, 2021 to 2032

Figure 84: Italy Market Share Analysis (%) by Infection, 2021 to 2032

Figure 85: Italy Market Share Analysis (%) by End User, 2021 to 2032

Figure 86: France Market Value Proportion Analysis, 2021

Figure 87: Global Vs France Growth Comparison, 2021 to 2032

Figure 88: France Market Share Analysis (%) by Test, 2021 to 2032

Figure 89: France Market Share Analysis (%) by Infection, 2021 to 2032

Figure 90: France Market Share Analysis (%) by End User, 2021 to 2032

Figure 91: Spain Market Value Proportion Analysis, 2021

Figure 92: Global Vs Spain Growth Comparison, 2021 to 2032

Figure 93: Spain Market Share Analysis (%) by Test, 2021 to 2032

Figure 94: Spain Market Share Analysis (%) by Infection, 2021 to 2032

Figure 95: Spain Market Share Analysis (%) by End User, 2021 to 2032

Figure 96: Russia Market Value Proportion Analysis, 2021

Figure 97: Global Vs Russia Growth Comparison, 2021 to 2032

Figure 98: Russia Market Share Analysis (%) by Test, 2021 to 2032

Figure 99: Russia Market Share Analysis (%) by Infection, 2021 to 2032

Figure 100: Russia Market Share Analysis (%) by End User, 2021 to 2032

Figure 101: BENELUX Market Value Proportion Analysis, 2021

Figure 102: Global Vs BENELUX Growth Comparison, 2021 to 2032

Figure 103: BENELUX Market Share Analysis (%) by Test, 2021 to 2032

Figure 104: BENELUX Market Share Analysis (%) by Infection, 2021 to 2032

Figure 105: BENELUX Market Share Analysis (%) by End User, 2021 to 2032

Figure 106: East Asia Market Value (US$ Million) Analysis, 2012 to 2021

Figure 107: East Asia Market Value (US$ Million) Forecast, 2022 to 2032

Figure 108: East Asia Market Value Share, by Test (2022 E)

Figure 109: East Asia Market Value Share, by Infection (2022 E)

Figure 110: East Asia Market Value Share, by End User (2022 E)

Figure 111: East Asia Market Value Share, by Country (2022 E)

Figure 112: East Asia Market Attractiveness Analysis by Test, 2022 to 2032

Figure 113: East Asia Market Attractiveness Analysis by Infection, 2022 to 2032

Figure 114: East Asia Market Attractiveness Analysis by End User, 2022 to 2032

Figure 115: East Asia Market Attractiveness Analysis by Country, 2022 to 2032

Figure 116: China Market Value Proportion Analysis, 2021

Figure 117: Global Vs. China Growth Comparison, 2021 to 2032

Figure 118: China Market Share Analysis (%) by Test, 2021 to 2032

Figure 119: China Market Share Analysis (%) by Infection, 2021 to 2032

Figure 120: China Market Share Analysis (%) by End User, 2021 to 2032

Figure 121: Japan Market Value Proportion Analysis, 2021

Figure 122: Global Vs. Japan Growth Comparison, 2021 to 2032

Figure 123: Japan Market Share Analysis (%) by Test, 2021 to 2032

Figure 124: Japan Market Share Analysis (%) by Infection, 2021 to 2032

Figure 125: Japan Market Share Analysis (%) by End User, 2021 to 2032

Figure 126: South Korea Market Value Proportion Analysis, 2021

Figure 127: Global Vs South Korea Growth Comparison, 2021 to 2032

Figure 128: South Korea Market Share Analysis (%) by Test, 2021 to 2032

Figure 129: South Korea Market Share Analysis (%) by Infection, 2021 to 2032

Figure 130: South Korea Market Share Analysis (%) by End User, 2021 to 2032

Figure 131: South Asia Market Value (US$ Million) Analysis, 2012 to 2021

Figure 132: South Asia Market Value (US$ Million) Forecast, 2022 to 2032

Figure 133: South Asia Market Value Share, by Test (2022 E)

Figure 134: South Asia Market Value Share, by Infection (2022 E)

Figure 135: South Asia Market Value Share, by End User (2022 E)

Figure 136: South Asia Market Value Share, by Country (2022 E)

Figure 137: South Asia Market Attractiveness Analysis by Test, 2022 to 2032

Figure 138: South Asia Market Attractiveness Analysis by Infection, 2022 to 2032

Figure 139: South Asia Market Attractiveness Analysis by End User, 2022 to 2032

Figure 140: South Asia Market Attractiveness Analysis by Country, 2022 to 2032

Figure 141: India Market Value Proportion Analysis, 2021

Figure 142: Global Vs. India Growth Comparison, 2021 to 2032

Figure 143: India Market Share Analysis (%) by Test, 2021 to 2032

Figure 144: India Market Share Analysis (%) by Infection, 2021 to 2032

Figure 145: India Market Share Analysis (%) by End User, 2021 to 2032

Figure 146: Indonesia Market Value Proportion Analysis, 2021

Figure 147: Global Vs. Indonesia Growth Comparison, 2021 to 2032

Figure 148: Indonesia Market Share Analysis (%) by Test, 2021 to 2032

Figure 149: Indonesia Market Share Analysis (%) by Infection, 2021 to 2032

Figure 150: Indonesia Market Share Analysis (%) by End User, 2021 to 2032

Figure 151: Malaysia Market Value Proportion Analysis, 2021

Figure 152: Global Vs. Malaysia Growth Comparison, 2021 to 2032

Figure 153: Malaysia Market Share Analysis (%) by Test, 2021 to 2032

Figure 154: Malaysia Market Share Analysis (%) by Infection, 2021 to 2032

Figure 155: Malaysia Market Share Analysis (%) by End User, 2021 to 2032

Figure 156: Thailand Market Value Proportion Analysis, 2021

Figure 157: Global Vs. Thailand Growth Comparison, 2021 to 2032

Figure 158: Thailand Market Share Analysis (%) by Test, 2021 to 2032

Figure 159: Thailand Market Share Analysis (%) by Infection, 2021 to 2032

Figure 160: Thailand Market Share Analysis (%) by End User, 2021 to 2032

Figure 161: Oceania Market Value (US$ Million) Analysis, 2012 to 2021

Figure 162: Oceania Market Value (US$ Million) Forecast, 2022 to 2032

Figure 163: Oceania Market Value Share, by Test (2022 E)

Figure 164: Oceania Market Value Share, by Infection (2022 E)

Figure 165: Oceania Market Value Share, by End User (2022 E)

Figure 166: Oceania Market Value Share, by Country (2022 E)

Figure 167: Oceania Market Attractiveness Analysis by Test, 2022 to 2032

Figure 168: Oceania Market Attractiveness Analysis by Infection, 2022 to 2032

Figure 169: Oceania Market Attractiveness Analysis by End User, 2022 to 2032

Figure 170: Oceania Market Attractiveness Analysis by Country, 2022 to 2032

Figure 171: Australia Market Value Proportion Analysis, 2021

Figure 172: Global Vs. Australia Growth Comparison, 2021 to 2032

Figure 173: Australia Market Share Analysis (%) by Test, 2021 to 2032

Figure 174: Australia Market Share Analysis (%) by Infection, 2021 to 2032

Figure 175: Australia Market Share Analysis (%) by End User, 2021 to 2032

Figure 176: New Zealand Market Value Proportion Analysis, 2021

Figure 177: Global Vs New Zealand Growth Comparison, 2021 to 2032

Figure 178: New Zealand Market Share Analysis (%) by Test, 2021 to 2032

Figure 179: New Zealand Market Share Analysis (%) by Infection, 2021 to 2032

Figure 180: New Zealand Market Share Analysis (%) by End User, 2021 to 2032

Figure 181: Middle East & Africa Market Value (US$ Million) Analysis, 2012 to 2021

Figure 182: Middle East & Africa Market Value (US$ Million) Forecast, 2022 to 2032

Figure 183: Middle East & Africa Market Value Share, by Test (2022 E)

Figure 184: Middle East & Africa Market Value Share, by Infection (2022 E)

Figure 185: Middle East & Africa Market Value Share, by End User (2022 E)

Figure 186: Middle East & Africa Market Value Share, by Country (2022 E)

Figure 187: Middle East & Africa Market Attractiveness Analysis by Test, 2022 to 2032

Figure 188: Middle East & Africa Market Attractiveness Analysis by Infection, 2022 to 2032

Figure 189: Middle East & Africa Market Attractiveness Analysis by End User, 2022 to 2032

Figure 190: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032

Figure 191: GCC Countries Market Value Proportion Analysis, 2021

Figure 192: Global Vs GCC Countries Growth Comparison, 2021 to 2032

Figure 193: GCC Countries Market Share Analysis (%) by Test, 2021 to 2032

Figure 194: GCC Countries Market Share Analysis (%) by Infection, 2021 to 2032

Figure 195: GCC Countries Market Share Analysis (%) by End User, 2021 to 2032

Figure 196: Turkey Market Value Proportion Analysis, 2021

Figure 197: Global Vs. Turkey Growth Comparison, 2021 to 2032

Figure 198: Turkey Market Share Analysis (%) by Test, 2021 to 2032

Figure 199: Turkey Market Share Analysis (%) by Infection, 2021 to 2032

Figure 200: Turkey Market Share Analysis (%) by End User, 2021 to 2032

Figure 201: South Africa Market Value Proportion Analysis, 2021

Figure 202: Global Vs. South Africa Growth Comparison, 2021 to 2032

Figure 203: South Africa Market Share Analysis (%) by Test, 2021 to 2032

Figure 204: South Africa Market Share Analysis (%) by Infection, 2021 to 2032

Figure 205: South Africa Market Share Analysis (%) by End User, 2021 to 2032

Figure 206: North Africa Market Value Proportion Analysis, 2021

Figure 207: Global Vs North Africa Growth Comparison, 2021 to 2032

Figure 208: North Africa Market Share Analysis (%) by Test, 2021 to 2032

Figure 209: North Africa Market Share Analysis (%) by Infection, 2021 to 2032

Figure 210: North Africa Market Share Analysis (%) by End User, 2021 to 2032